Objective: The aim of this study is to investigate the effects of exercise as an add-on therapy with antidepressant medication and cognitive behavioral group therapy (CBGT) on treatment outcomes in low-active major depressive disorder (MDD) patients. We also explored whether exercise reduces the residual symptoms of depression, notably cognitive impairment and poor sleep quality, and aimed to identify putative biochemical markers related to treatment response. Methods: Sixteen low-active MDD patients were recruited from a mental health day treatment program at a local hospital. Eight medicated patients performed an 8-week exercise intervention in addition to CBGT, and eight medicated patients attended the CBGT only. Twenty-two low-active, healthy participants with no history of mental health illness were also recruited to provide normal healthy values for comparison. Results: Results showed that exercise resulted in greater reduction in depression symptoms (p = 0.007, d = 2.06), with 75% of the patients showing either a therapeutic response or a complete remission of symptoms vs. 25% of those who did not exercise. In addition, exercise was associated with greater improvements in sleep quality (p = 0.046, d = 1.28) and cognitive function (p = 0.046, d = 1.08). The exercise group also had a significant increase in plasma brain-derived neurotrophic factor (BDNF), p = 0.003, d = 6.46, that was associated with improvements in depression scores (p = 0.002, R² = 0.50) and sleep quality (p = 0.011, R² = 0.38). Conclusion: We provide evidence that exercise as an add-on to conventional antidepressant therapies improved the efficacy of standard treatment interventions. Our results suggest that plasma BDNF levels and sleep quality appear to be good indicators of treatment response and potential biomarkers associated with the clinical recovery of MDD.

Study Design. Reliability study. Objective. To determine the reproducibility of the cervical flexion-relaxation ratio (FRR) measured 4 weeks apart in a group of chronic neck pain patients and healthy control group and to compare the FRR between the 2 groups. Summary of Background Data. The cervical FRR measures the ability of the neck extensor muscles to relax during forward flexion, similar to the lumbar FRR. Its reliability and ability to discriminate neck pain patients from controls has not been investigated. Methods. Fourteen participants with chronic neck pain and a control group of 14 individuals with no neck pain were recruited via advertisement and word of mouth. The cervical FRR was determined at baseline and 4 weeks later using standardized electromyographic data collection and analysis procedures. Results. The mean FRR value for the combined left and right side data for the neck pain groups was 1.93 ± 0.8, and 1.73 ± 0.61 at 4-week follow-up. The intraclass correlation coefficient (ICC) was 0.83 (95% CI = 0.67–0.92). Three participants in the control group developed neck pain in the 4 weeks and their data were not included in the reliability calculation. For the control group, the combined (left and right side) mean FRR value was 4.09 ± 1.58 at baseline and 4.27 ± 1.71 on retest 4 weeks later. The ICC (intraclass r) was 0.89 (95% confidence interval = 0.76–0.95). The overall ICC for the combined groups was 0.92 (95% confidence interval = 0.86–0.95). An independent 2 group t test revealed a significant difference in the baseline FRR data between the control group and the neck pain group (P < 0.001). Conclusion. The cervical extensor muscles exhibit a consistent flexion-relaxation phenomenon in healthy control subjects and the measurement is highly reproducible when measured 4 weeks apart in both controls and chronic neck pain patients. The FRR in neck pain patients is significantly higher than in control subjects suggesting that this measure may be a useful marker of altered neuromuscular function.